Overview
- Magnani, F. et al. (2014) ACS Chem. Biol. 9, 1420.
- Ishiguro, S. et al. (2015) Cancer Biol. Ther. 16, 307.
![Alomone Labs [Y]6-Angiotensin II Analog induces ERK1/2 (p42/44 MAPK) phosphorylation in IEC-6 cells.](http://alomone.supremeclients.com/wp-content/uploads/2018/10/SPA-175_WB.gif)
Alomone Labs [Y]6-Angiotensin II Analog induces ERK1/2 (p42/44 MAPK) phosphorylation in IEC-6 cells.Serum-deprived cells were stimulated for 5 min with 0 nM, 1 nM, 10 nM and 100 nM [Y]6-Angiotensin II Analog (#SPA-175) or with 100 nM Angiotensin II (#GPA-100). Cell proteins were resolved by SDS-PAGE and probed with anti-phospo-ERK1/2.
Y6-Angiotensin II Analog is a potent and selective agonist of Angiotensin II type 2 receptor (AT2R)1. Studies show that it can be used as a safe and effective therapeutic tool for pancreatic ductal adenocarcinoma1.
Local administration of Y6-Angiotensin II Analog causes AT2R gene expression in tumor cells and significantly attenuates the growth of fast growing murine pancreatic ductal adenocarcinoma tumors. This evidence may suggest that AT2R agonist therapy is an effective and useful procedure for pancreatic ductal adenocarcinoma treatment2.
Y6-Angiotensin II Analog shows two distinct sets of proton resonances in aqueous solution, cis and trans conformations1. The cis isomer contains aromatic rings of Tyr6 and Phe8 stacked around the Pro7 ring, thus leading to a compact hydrophobic motif1.
Angiotensin II type 2 receptor belongs to the superfamily of G-protein coupled receptors. The receptor mediates angiotensin II actions involved in vasodilation and anti-proliferation2.
